Cardiologists track the pace at which lipoprotein-associated phospholipase A2 converts substrate inside the bloodstream, using that rate to flag silent inflammation quietly damaging artery walls. The enzyme gets produced by immune cells buried inside atherosclerotic plaques, the fatty buildup that narrows arteries over time. Most of the molecules ride around attached to LDL particles, the same carriers that move cholesterol through your blood.
Because the enzyme reacts with oxidized phospholipids on those LDL surfaces, it generates pro-inflammatory lipid byproducts that keep plaques unstable.
If you’re weighing a blood test that goes beyond standard cholesterol numbers, this walkthrough breaks down what Lp-PLA2 activity actually means and why cardiologists lean on it as a quiet warning sign for plaque-driven inflammation.
Lp-PLA2 and the Biology of Vascular Inflammation
The Lp-PLA2 enzyme, encoded by the PLA2G7 gene, behaves differently from the phospholipases that handle routine fat digestion. It floats through the circulation in a calcium-independent form, attached mostly to LDL cholesterol in a ratio that researchers have measured at roughly four to one. Wherever LDL gets trapped inside artery walls, the enzyme travels with it, ready to act on the oxidized phospholipids accumulating in damaged tissue.
Where the Enzyme Originates and Where It Acts
Most Lp-PLA2 in plaques comes from monocytes and macrophages, the cleanup cells of the immune system that flood into arterial lesions. Inside the vessel wall, the enzyme cleaves oxidized phospholipids and releases two signaling molecules: lysophosphatidylcholine and oxidized free fatty acids. Those byproducts attract more immune cells, weaken the fibrous cap covering each plaque, and promote the kind of inflammation that can rupture a plaque and trigger a heart attack or ischemic stroke.
Why the Lipoprotein Connection Matters
The LDL-binding habit separates this phospholipase from other inflammatory markers. Standard inflammation tests like hs-CRP rise whenever the body fights infection, heals a wound, or deals with arthritis flares. Lp-PLA2 stays relatively specific to the vascular wall, which gives it a tighter signal when the question is whether arteries themselves are inflamed. That specificity shaped the original PLAC test developed by diaDexus, the first commercial assay designed to measure the enzyme in clinical practice.
Activity Versus Mass: What the Test Actually Measures
Two commercial approaches exist, and they answer different questions. Activity assays measure how much substrate the enzyme actually converts per minute, expressed in nanomoles per minute per milliliter. Mass assays measure the total concentration of Lp-PLA2 protein in the blood, regardless of whether each molecule is functionally active.
Side-by-Side Comparison of the Two Assays
| Feature | Lp-PLA2 Activity Assay | Lp-PLA2 Mass Assay |
|---|---|---|
| What it measures | Functional enzyme rate | Total protein concentration |
| Reported units | nmol/min/mL | ng/mL |
| What affects the result | Actual catalytic behavior | Amount of circulating protein |
| Clinical interpretation | Reflects active inflammation | Reflects enzyme burden only |
| Use case | Cardiovascular risk refinement | Research and select lab panels |
Two patients can post nearly identical mass readings and still show very different activity levels if one person’s enzyme molecules are working overtime while the other’s sit idle. Clinicians who want a true inflammation signal tend to order activity testing rather than mass testing. The activity number captures kinetics, the real-time pace at which the enzyme generates inflammatory byproducts inside your arteries.
That kinetics-driven measurement is what makes the numerical cutoff clinically meaningful in the first place.
Normal and Elevated Lp-PLA2 Activity Ranges
Most reference laboratories draw the normal cutoff at 200 nmol/min/mL, though the exact threshold shifts depending on the assay manufacturer running the test. Values between roughly 150 and 200 nmol/min/mL are often classified as borderline, while readings above 200 nmol/min/mL generally flag moderate vascular inflammation. Numbers beyond 225 nmol/min/mL typically place someone in a higher cardiovascular risk tier and prompt a more aggressive look at prevention.
How Stable the Reading Is Over Time
Unlike cholesterol or blood sugar, the enzyme level drifts slowly, so a single measurement often reflects your baseline pattern rather than a transient spike. Day-to-day variation is modest unless you are fighting an acute infection or recovering from surgery, both of which can temporarily push numbers higher.
That stability makes the test useful for risk stratification, because a single elevated reading is unlikely to be a fluke and usually points to a real, ongoing inflammatory process in the vessel wall.
Tip: ask the lab which assay they ran. An activity value reported in nmol/min/mL is not interchangeable with a mass value reported in ng/mL, and mixing them up leads to bad interpretations.
Lp-PLA2 Activity as a Signal for Atherosclerosis and Stroke
Large observational studies have repeatedly connected elevated activity to higher rates of coronary heart disease and ischemic stroke, often independent of LDL cholesterol levels. In some analyses, the marker added predictive power on top of the Framingham risk score, helping reclassify patients from intermediate to higher risk when other variables looked borderline.
What Sets It Apart From hs-CRP
The biggest practical difference between this marker and hs-CRP is location. C-reactive protein rises with any systemic inflammation, including a sinus infection, a sprained ankle, or active arthritis. Lp-PLA2 tracks inflammation confined to the vascular wall, because that is where the enzyme is produced and where it does its work. When hs-CRP and Lp-PLA2 move in the same direction, the suspicion of true vascular inflammation grows stronger.
Where the Marker Adds the Most Value
Cardiologists tend to lean on the result when someone lands in the gray zone of risk, an LDL that looks acceptable, a Framingham score that sits just under the treatment threshold, or a family history suggesting trouble brewing earlier than standard models predict. In those cases, an elevated activity number can tip the decision toward earlier preventive therapy or more frequent imaging surveillance.
A patient with an unexplained cardiovascular event at a relatively young age is another common trigger for testing.
These testing triggers have accumulated faster than guideline committees have been willing to formalize them.
Where Lp-PLA2 Sits in Current Clinical Guidelines
Major bodies have weighed in carefully. Earlier statements from the American Heart Association listed Lp-PLA2 among markers that could refine risk assessment in selected adults, but the recommendation stopped short of universal screening. The National Cholesterol Education Program and later ACC/AHA cholesterol guidelines have consistently focused on LDL cholesterol and overall risk calculators as the primary drivers of treatment decisions, with Lp-PLA2 reserved for cases where the picture stays unclear.
Why the Enthusiasm Cooled
The turning point came with large Phase III trials of darapladib, an Lp-PLA2 inhibitor designed to suppress enzyme activity and reduce cardiovascular events. Despite lowering the marker substantially, the drug failed to reduce heart attacks or strokes in the studied populations, which dampened hope that blocking the enzyme alone would change outcomes. That disappointment reframed the marker as a window into vascular inflammation rather than a direct lever to pull.
Who Still Gets Tested
Testing today tends to land in three situations: adults at intermediate cardiovascular risk who need one more piece of data, people who suffered an unexplained cardiac event and lack the usual risk factors, and patients with autoimmune conditions that already predispose them to vascular inflammation. Routine annual screening in low-risk adults remains uncommon, partly because insurance coverage varies and the result rarely changes management when other markers already point the right direction.
Practical Steps After Receiving an Lp-PLA2 Result
A single number rarely tells the whole story, so pairing it with other markers sharpens the picture considerably. Most cardiologists want to see the activity result alongside a full lipid panel and hs-CRP, because the three together describe both cholesterol burden and the inflammation riding on top of it. Imaging like a coronary artery calcium scan may also be ordered when the result sits in a borderline range.
Build a Complete Inflammation Picture
- Add a full lipid panel: LDL, HDL, and triglycerides give context that the activity number alone cannot.
- Pair with hs-CRP: matching elevations strengthen the case for vascular inflammation.
- Consider a coronary calcium score: imaging can confirm whether plaque has actually built up.
- Review family history: a strong family history magnifies the meaning of any borderline number.
Move the Marker in the Right Direction
Lifestyle measures that lower LDL cholesterol tend to pull Lp-PLA2 activity down as a secondary benefit, which is one reason clinicians start with the basics. A Mediterranean-style eating pattern, regular aerobic exercise, weight loss when indicated, and smoking cessation all shift the underlying vascular environment. When those steps fall short, lipid-lowering therapy has been shown in some studies to reduce activity alongside LDL, though the relationship is not as dramatic as the cholesterol effect.
Always discuss medication decisions with your cardiologist rather than starting anything on your own.
Plan the Next Recheck
Repeating the test on a fixed schedule rarely adds useful information, because the enzyme drifts slowly. Recheck activity only when your clinician suspects a meaningful change, such as after starting a new therapy, recovering from a major inflammatory event, or following up on a borderline reading that prompted closer monitoring. That approach keeps the test useful without turning it into a routine expense.
A clear action plan is only useful if you can distill it into a single takeaway.
Bottom Line
Cardiologists get a focused view of inflammation inside artery walls from Lp-PLA2 activity, separate from the systemic inflammation tracked by hs-CRP and the cholesterol burden measured in a standard lipid panel. An elevated result adds useful weight to intermediate-risk calculations and clarifies ambiguous cases, yet it has not become a universal screen because blocking the enzyme alone did not change outcomes in large trials.
Pair it with other markers, lean into lifestyle measures that lower LDL, and let your clinician decide whether repeat testing will actually change your management plan.
FAQ
What does Lp-PLA2 activity indicate?
It indicates how actively the Lp-PLA2 enzyme is generating inflammatory byproducts inside atherosclerotic plaques, providing a more vascular-specific inflammation signal than general markers like hs-CRP.
Why is Lp-PLA2 activity measured?
Clinicians order it to refine cardiovascular risk assessment in adults who fall into the intermediate-risk category or who experienced an unexplained cardiac event without classic risk factors.
What is the normal range for Lp-PLA2 activity?
Most laboratories consider values below 200 nmol/min/mL as normal, while readings above 225 nmol/min/mL typically signal substantially higher cardiovascular risk and prompt further evaluation.
How is Lp-PLA2 activity different from Lp-PLA2 mass?
Activity assays measure the enzyme’s functional rate in nmol/min/mL, whereas mass assays simply quantify total protein concentration in ng/mL, so two patients with the same mass can have very different activity levels.
Can Lp-PLA2 activity predict heart attack or stroke?
Elevated activity is associated with higher rates of coronary heart disease and ischemic stroke in observational studies and adds predictive value on top of standard risk calculators, though it does not predict events on its own with certainty.
Is Lp-PLA2 activity testing still recommended?
Major societies consider it useful for refining risk in selected patients but do not endorse universal screening, partly because large trials of Lp-PLA2 inhibitors failed to reduce cardiovascular events.
